The Elsevier Office of Continuing Medical Education and AcademicCME appreciate your opinions to help assist us in the evaluation of the effectiveness of this activity and to identify your ongoing educational needs.

Please complete this evaluation form.  You must complete this evaluation form to receive acknowledgement for completing this activity.

*
*
*
*
*
*
*
*
PoorFairGoodVery goodExcellent
Discuss the science of PCSK9 inhibitor therapeutics and the current ACC/AHA/NLA guidelines for patients with dyslipidemia.
Analyze clinical trial data for PCSK9 inhibitor therapeutics.
Integrate personalized treatment plans for patients with statin intolerance, familial hypercholesterolemia, and dyslipidemia patients not at LDL-C goal.
*
NeverRarelySometimesMost of the timeAlwaysN/A
Understand and apply PCSK9 therapeutics for the treatment of patients with dyslipidemia.
Consider recent clinical trial data when developing personalized treatment plans for patients with statin intolerance, familial hypercholesterolemia, and dyslipidemia patients not at LDL-C goal.
*
Please use the scale: 1=Never, 2=Rarely, 3=Sometimes, 4=Most of the time, 5=Always, N/A=Not applicable for me
NeverRarelySometimesMost of the timeAlwaysN/A
Understand and apply PCSK9 therapeutics for the treatment of patients with dyslipidemia.
Consider recent clinical trial data when developing personalized treatment plans for patients with statin intolerance, familial hypercholesterolemia, and dyslipidemia patients not at LDL-C goal.
*
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Overall, this activity met my learning needs
The information presented was without promotional or commercial bias
Was scientifically rigorous and evidence based
Provided appropriate and effective opportunities for active learning (e.g., discussion, Q & A)
The quality of the educational process was satisfactory and appropriate
Promoted improvements or quality in healthcare
The information provided with regard to faculty financial relationships met my needs for disclosure
The speakers were knowledgeable and presented the information clearly
The format of the discussion was relevant and enhanced my knowledge of the subject
*
PoorFairGoodVery goodExcellent
James A. Underberg, MD
Peter H. Jones, MD
Michael J. Blaha, MD, MPH
Elizabeth J. Jackson, MSN, ACNS-BC
*
*

Attestation to time spent on activity:

The Elsevier Office of Continuing Medical Education designates this live activity for a maxiumum of 2.0 AMA PRA Category 1 CreditsTM.

*

The EOCME and AcademicCME thank you for your participation in this activity.

All information provided improves the scope and purpose of our programs.